F. No. ND/CT/23/000055
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
New Drugs Division

FDA Bhawan, Kotla Road,
New Delhi-110002

To
M/s Galderma India Private Limited,
8th Floor, D Wing, Unit 801 &802, G Wing,
802, Lotus Corporate Park, Off Western Express Highway
Goregaon (East), India-400063

Subject: Permission to conduct Phase-IV Clinical Trial of Trifarotene 50 µg/g cream "A prospective, multi-center, open-label Phase IV clinical study to evaluate the safety and efficacy of trifarotene (Aklief) 50µg/g cream in subjects with acne vulgaris over 12 weeks."– regarding.

Ref: Your application no. ND/CT04/FF/2023/38184 dated 30.06.2023

Sir,

With reference to your application, please find enclosed herewith the permission in **Form CT-06 vide no. CT/ND/43/2023** to conduct the subject mentioned clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

This permission is subject to the conditions, as mentioned below.

Yours faithfully

RAJEEV SINGH RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL ORGANIZATION, ou=RAJEEV SINGH RAGHUVANSHI, 2.5.4.20=80c62f6a23e4eafbe8a239774cdeb03c2769041015a06564fe67f54b765db1cb, postalCode=600034, st=TAMIL NADU, serialNumber=657F5E47D940985D8F03BDC902D0E1FE73CFA12A1A126EA94FA5701124A19013, cn=RAJEEV SINGH RAGHUVANSHI
Date: 2024.01.15 11:41:28 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Central Licensing Authority

Condition of permission

(i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under Rule 8;

(ii) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics

Committee for clinical trial constituted in accordance with the provisions of Rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

(iii) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

(iv) The Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

(v) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;

(vi) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

(vii) Status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;

(viii) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority;

(ix) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;

(x) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI of the New Drugs and Clinical Trials Rules, 2019;

(xi) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with the Chapter VI of the said Rules and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;

(xii) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with

the Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;

(xiii) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorized by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;

(xiv) Where the New Drug or Investigational New Drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;

(xv) The Laboratory owned by any person or a company or any other legal entity and utilized by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;

(xvi) The Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;

(xvii) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

(xviii) Informed Consent Documents (ICD) viz. Patient Information Sheet (PIS) and Informed Consent Form (ICF) complete in all respect & must be got approved from the respective Ethics committee and submitted to CDSCO before enrolling first subject at the respective site.

(xix) The informed Consent Document including ICF and Patient Information Sheet should clearly mention in understandable language about the details of the drug therapy that the patient may or may not receive.

(xx) It may kindly be noted that merely granting permission to conduct Clinical Trial study with drug doesn't convey or imply that based Clinical Trial data generated with the drug, permission to market this drug will automatically be granted to you.

(xxi) **The firm to conduct an active controlled comparative study with their drug product Trifarotene 50µg/g cream with already available treatments in the country.**

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

Permission No. CT/ND/43/2023

The Central Licensing Authority hereby permits **M/s Galderma India Private Limited, 8th Floor, D Wing, Unit 801 & 802, G Wing, 802, Lotus Corporate Park, Off Western Express Highway Goregaon (East), India-400063,** Telephone No. 02240331818, Fax: 02240331807, E-Mail: REGULATORY.GALINDIA@GALDERMA.COM, to conduct clinical trial of the new drug or investigational new drug as per **Protocol No.RD.30.SPR.205051, Version No. 00 Protocol Date 28-JUN-2023** in the below mentioned clinical trials sites.

2. Details of new drug or investigational new drug and clinical trial site:-

Names of the new drug or investigational new drug:	Trifarotene 50µg/g (0.005%w/w) Cream
Therapeutic class:	Antiacne
Dosage form:	Cream
Composition:	Each gram of Trifarotene cream contains 50 mcg of Trifarotene
Indication:	Indicated for the cutaneous treatment of Acne Vulgaris of the face and /or trunk in patients 12 years of age and older.

Details of clinical trial sites-

Sr. No.	Name of Principal Investigator & Trial Sites	Ethics Committee Name/ Registration Number
01	**Dr. Sanjeev Handa,** Post Graduate Institute of Medical Education & Research, 6006, 6th Floor, PN Chuttani Block, PGIMER Block, PGIMER, Sector-12, Chandigarh-160012	Institutional Ethics Committee PGIMER, Address: #6006, 6th Floor, PN Chuttani Block, PGIMER Block, PGIMER, Sector-12, Chandigarh-160012 **ECR/25/Inst/CH/2013/RR-20**
02	**Dr. Somesh Gupta,** All India Institute of Medical Sciences, Ethics Committee, All India Institute of Medical Sciences, Room No. 102, 1st Floor, Old O.T Block, Ansari Nagar, New Delhi	AIIMS, Institute Ethics Committee (IEC), Room No. 102, 1st Floor, Old O.T Block, Ansari Nagar, South Delhi, Delhi-110029 **ECR/538/Inst/DL/2014/RR-20**
03	**Dr. Sushil Tahiliani,** Dr. Tahiliani Clinic, A-201/202, Gasper enclave, Dr. Ambedkar Road, Next to Gold gym, Pali market, Bandra West, Mumbai - 400050	V Care Independent Ethics Committee Can Cure Day Care Centre, Fr. Agnel College, Sector 9A, Vashi-Navi Mumbai, Next to Noor Masjid, Vashi, Navi Mumbai 400703, Thane. **ECR/334/Indt/MH/2020**
04	**Dr. Surajit Gorai,** Apollo Gleneagles Hospital Institutional	Institutional Ethics Committee, Apollo Gleneagles Hospital Institutional

	Ethics Committee, Apollo Gleneagles, Hospital Kolkata, 58, Canal Circular Road, Kolkata, West Bengal 700054	Ethics Committee, Apollo Gleneagles, Hospital Kolkata, 58, Canal Circular Road, Kolkata, West Bengal **ECR/373/Inst/WB/2013/RR-19**
05	**Dr. Malathi Munisamy** Jawaharlal Institute of Post Graduate Medical Education and Research, JIPMER Campus Road, JIPMER, Dhavantari Nagar, Pondicherry, Puducherry	Institutional Ethics Committee for Intervention Studies, JIPMER, Dhavantari Nagar, Pondicherry **ECR/342/Inst/PY/2013/RR-19**
06	**Dr. BS Chandrashekar** CUTIS Academy of Cutaneous Sciences, 5/1, 4th Main, MRCR Layout, Vijay nagar (near Veeresh Theatre), Magadi Main road, Bengaluru-560040	CUTIS INSTITUTIONAL ETHICS COMMITTEE, CUTIS Academy of Cutaneous Sciences, 5/1,4th Main, MRCR Layout Vijayanagar, Bangalore Near Veerash Cinema Theater Bengaluru (Bangalore), Urban Karnataka - 560040 India **ECR/930/Inst/KA/2017/RR-20**
07	**Dr. Hari Kishan Kumar Y** Rajarajeshwari Medical College and Hospital, 202, Kambipura, Mysore Road, Bengaluru-560074	Institutional Ethics Committee, Rajarajeshwari Medical College and Hospital, 202, Kambipura, Mysore Road, Bengaluru-560074 **ECR/56/Inst/KA/2013/RR-19**
08	**Dr. Abhishek De** Wizderm Specialty Skin And Hair Clinic 1st floor, Onex Square, 75, Shakespeare Sarani Rd, Kolkata- 700017, West Bengal, India	HP Poddar Memorial Clinic And Nursing Home, 56H, Beleghata Main Rd, Subhas Sarobar Park Phool Bagan, Beleghata, Kolkata Kolkata Kolkata West, Bengal - 700010 India **ECR/1555/Inst/WB/2021**
09	**Dr. Shivakumar Patil** KLE Dr.Prabhakar Hospital and Medical Research Centre, Nehru Nagar, Belagavi (Belgaum), Karnataka - 590010 India	Institutional Ethics Committee, KLE University, KLE University KLE Dr.PK Hospital and MRC, Nehru Nagar Belagavi (Belgaum) Karnataka - 590010 India **ECR/211/Inst/KA/2013/RR-19**

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

RAJEEV SINGH RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL ORGANIZATION, ou=RAJEEV SINGH RAGHUVANSHI, 2.5.4.20=80c62f6a23e4eafbe8a239774cdeb03c2769041015a06564fe67f54b765db1cb, postalCode=600034, st=TAMIL NADU, serialNumber=657F5E47D940985D8F038DC902D0E1FE73CFA12A1A126EA94FA5701124A19013, cn=RAJEEV SINGH RAGHUVANSHI
Date: 2024.01.15 11:42:02 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Central Licensing Authority

New Delhi